Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update.
Cuisset
Thomas
T
Department of Cardiology, University Hospital La Timone, Marseille, France. thomascuisset@voila.fr
Valgimigli
Marco
M
Mudra
Harald
H
Muller
Olivier
O
Wijns
William
W
Huber
Kurt
K
D054058:Acute Coronary Syndrome / Q000628:therapy*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors